文献速递肾移植

BCMA靶向T细胞衔接疗法联合B细胞清除治疗难治性HLA致敏

B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization.
PubMed 文献 · Kidney Int · 2026-02-13

本病例报告描述一名37岁女性终末期肾病患者,因极高度HLA致敏(cPRA>99.9%)20年未能获得合适供肾。

要点

  • 奥妥珠单抗联合elranatamab可深度清除记忆B细胞和浆细胞,显著降低高滴度抗HLA抗体。
  • 该方案耐受性良好,仅出现一过性无症状细胞因子释放综合征,保护性免疫通过免疫球蛋白替代维持。

核心结论

  • BCMA靶向T细胞衔接疗法联合B细胞清除策略实现了前所未有的高滴度预存抗HLA抗体清除,为难治性致敏患者提供了有前景的脱敏方案。

研究设计与样本

  • 单例病例报告:37岁女性,NPHS2相关肾病综合征导致肾衰竭,cPRA>99.9%,活跃等待供肾20年未获合适移植。
  • 既往6至17岁间曾接受肾移植,4年前达雷妥尤单抗脱敏方案失败。
  • 在同情用药下接受奥妥珠单抗(II型人源化抗CD20抗体)联合elranatamab(BCMA靶向T细胞衔接器)挽救性治疗。

主要发现

  • 两种药物耐受良好,仅首次elranatamab剂量后出现一过性无症状细胞因子释放综合征。
  • 联合治疗使cPRA在6个月内从99.96%降至0%。
  • 除自限性沙波病毒腹泻外无感染事件,保护性免疫通过免疫球蛋白替代维持。
  • 脱敏成功后接受肾移植,跨越低水平供者特异性抗体(DSA),术后DSA未反弹。

关键数值与推荐

  • cPRA从99.96%降至0%(6个月内)。
  • 免疫抑制方案:巴利昔单抗非淋巴细胞清除性诱导,三联维持治疗,并将霉酚酸迅速转换为依维莫司。

临床怎么用

  • 对于极高度HLA致敏且传统脱敏无效的患者,可考虑BCMA靶向T细胞衔接器联合B细胞清除作为挽救性脱敏策略。
  • 治疗期间需监测细胞因子释放综合征,并通过免疫球蛋白替代维持保护性免疫。
  • 脱敏成功后肾移植可采用非淋巴细胞清除性诱导,并需个体化维持免疫抑制方案。

局限性

  • 单例病例报告,结论的普遍适用性需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Preformed, high-titer anti-human leukocyte antigen (HLA) antibodies remain a major barrier to successful kidney transplantation, increasing the risk of early graft loss and prolonged time on dialysis. Despite advances in desensitization, current therapies are largely ineffective for patients with extremely high antibody levels. METHODS: Here, we report the case of a 37-year-old woman with kidney failure secondary to NPHS2-related nephrotic syndrome who received no suitable transplant offer despite 20 years of active listing, owing to extreme HLA sensitization (calculated Panel Reactive Antibody [cPRA] over 99.9%). She had previously been transplanted from age six to 17. Following the failure of a daratumumab-based desensitization regimen four years earlier, immunologic evaluation indicated the need for concurrent, potent depletion of memory B cells and plasma cells. This prompted a salvage regimen, administered under compassionate use, combining a type II humanized anti-CD20 antibody (obinutuzumab) with a B-cell maturation antigen (BCMA)-targeted T-cell engager (elranatamab). RESULTS: Both agents were well tolerated; only a transient, asymptomatic cytokine release syndrome occurred after the initial elranatamab dose. The combination produced a profound reduction in anti-HLA antibodies, decreasing the cPRA from 99.96% to 0% within six months. Protective immunity was maintained with immunoglobulin replacement. Apart from a self-limited episode of sapovirus-induced diarrhea, no infectious events occurred. Following successful desensitization, the patient underwent an uneventful kidney transplantation across low-level donor-specific antibodies (DSAs), which did not rebound post-transplant. The immunosuppressive regimen consisted of non-lymphodepletive induction with basiliximab, followed by a triple-drug maintenance therapy, including a prompt conversion from mycophenolic acid to everolimus. At ten months post-transplant, she remained free of rejections, with excellent graft function, low urinary chemokine levels, and persistently negative donor-specific antibodies. CONCLUSIONS: This dual-agent immunotherapeutic strategy achieved unprecedented depletion of high-titer, preformed anti-HLA antibodies and represents a promising approach for patients with prohibitive sensitization.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Leon J, Aubert O, Devriese M, et al. B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization. Kidney Int. 2026. PMID: 41692345. doi:10.1016/j.kint.2026.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。